Absence of p16/MTS1 gene mutations in human prostate cancer. Carcinogenesis 1996 Dec;17(12):2603-7
Date
12/01/1996Pubmed ID
9006095DOI
10.1093/carcin/17.12.2603Scopus ID
2-s2.0-0030464202 (requires institutional sign-in at Scopus site) 32 CitationsAbstract
The tumor suppressor gene p16/MTS1, located on chromosome 9p21, is a cell cycle regulatory gene which is frequently altered in human cancers. The role of this gene in prostate cancer is unknown. To determine the frequency of deletions and point mutations of p16/MTS1 in human prostate cancer, we examined 18 cancer and matched benign and hyperplastic tissue specimens. Deletions of p16/MTS1 were detected by semi-quantitative multiplex polymerase chain reaction in which a portion of exon 2 of the p16/MTS1 gene and a control marker, the glyceraldehyde 3-phosphate dehydrogenase gene, were amplified simultaneously. 'Cold' single-stranded conformational polymorphism (SSCP) analysis was performed to examine exons 1 and 2 of the p16/MTS1 gene for point mutations. Our data indicate no evidence for intragenic homozygous deletion in the prostate tumors. One prostate tumor and matched benign tissue showed mobility shifts. Direct DNA sequencing of the SSCP positive samples showed a G --> A transition in codon 140 which would result in an amino acid change from alanine to threonine. Our results indicate that deletions and point mutations in the p16/MTS1 gene are rare and do not play a major role in human prostate carcinogenesis.
Author List
Chen W, Weghorst CM, Sabourin CL, Wang Y, Wang D, Bostwick DG, Stoner GDMESH terms used to index this publication - Major topics in bold
AgedCarrier Proteins
Cyclin-Dependent Kinase Inhibitor p16
Genes, Tumor Suppressor
Humans
Male
Middle Aged
Point Mutation
Polymerase Chain Reaction
Polymorphism, Single-Stranded Conformational
Prostatic Neoplasms